Antithrombotic therapy for congestive heart failure

I Chung, Gregory Lip

Research output: Contribution to journalArticle

12 Citations (Scopus)


Patients with congestive heart failure (CHF) are at increased risk of thromboembolic events. However, there is much debate and uncertainty over the use of antithrombotic therapy in these patients. The evidence for oral anticoagulation is limited, although large randomised trial data are forthcoming. Aspirin may be detrimental for heart failure due to a possible interaction with angiotensin-converting enzyme inhibitors, leading to increased hospitalisations from decompensated heart failure. The objective of this review article is to summarise the available evidence regarding the risk of stroke and thromboembolic events in CHF patients, as well as the effectiveness and risks of antithrombotic therapy in these patients.
Original languageEnglish
Pages (from-to)36-47
Number of pages12
JournalInternational Journal of Clinical Practice
Issue number1
Publication statusPublished - 1 Jan 2006


Dive into the research topics of 'Antithrombotic therapy for congestive heart failure'. Together they form a unique fingerprint.

Cite this